Effects of chlorpheniramine on emergence agitation after general anesthesia for ureteroscopic stone surgery: a retrospective cohort study.
Anesthesia
Chlorpheniramine
Emergence agitation
Incidence
Urinary catheter
Journal
Anesthesia and pain medicine
ISSN: 2383-7977
Titre abrégé: Anesth Pain Med (Seoul)
Pays: Korea (South)
ID NLM: 101517708
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
22
06
2021
accepted:
04
08
2021
pubmed:
17
11
2021
medline:
17
11
2021
entrez:
16
11
2021
Statut:
ppublish
Résumé
The presence of a urinary catheter, postoperative pain, and postoperative nausea and vomiting are risk factors for emergence agitation (EA). Antimuscarinic agents are primary agents used in the prevention and treatment of urinary catheter-related bladder discomfort. Chlorpheniramine has antimuscarinic, antinociceptive, and antiemetic effects. This retrospective study investigated the role of chlorpheniramine in EA prevention following ureteroscopic stone surgery. Of 110 adult patients who underwent ureteroscopic stone surgery under general anesthesia between January and December 2019, the medical records of 93 patients were analyzed retrospectively. The patients were divided into control (n = 52) and chlorpheniramine (n = 41) groups according to the receipt of intravenous chlorpheniramine before the induction of anesthesia. The incidence and severity of EA were compared between the groups as primary and secondary endpoints, respectively. The effects of chlorpheniramine on the requirement for inhalation anesthetic (desflurane) during surgery, changes in mean blood pressure and heart rate during emergence, and adverse events were also compared. The incidence (21.2% in the control group, 24.4% in the chlorpheniramine group) and severity of EA did not differ between groups. The intraoperative requirement for desflurane, changes in mean blood pressure and heart rate during emergence, and adverse events were also similar between groups. Chlorpheniramine was not associated with a decrease in EA incidence or severity in patients who underwent ureteroscopic stone surgery.
Sections du résumé
BACKGROUND
BACKGROUND
The presence of a urinary catheter, postoperative pain, and postoperative nausea and vomiting are risk factors for emergence agitation (EA). Antimuscarinic agents are primary agents used in the prevention and treatment of urinary catheter-related bladder discomfort. Chlorpheniramine has antimuscarinic, antinociceptive, and antiemetic effects. This retrospective study investigated the role of chlorpheniramine in EA prevention following ureteroscopic stone surgery.
METHODS
METHODS
Of 110 adult patients who underwent ureteroscopic stone surgery under general anesthesia between January and December 2019, the medical records of 93 patients were analyzed retrospectively. The patients were divided into control (n = 52) and chlorpheniramine (n = 41) groups according to the receipt of intravenous chlorpheniramine before the induction of anesthesia. The incidence and severity of EA were compared between the groups as primary and secondary endpoints, respectively. The effects of chlorpheniramine on the requirement for inhalation anesthetic (desflurane) during surgery, changes in mean blood pressure and heart rate during emergence, and adverse events were also compared.
RESULTS
RESULTS
The incidence (21.2% in the control group, 24.4% in the chlorpheniramine group) and severity of EA did not differ between groups. The intraoperative requirement for desflurane, changes in mean blood pressure and heart rate during emergence, and adverse events were also similar between groups.
CONCLUSIONS
CONCLUSIONS
Chlorpheniramine was not associated with a decrease in EA incidence or severity in patients who underwent ureteroscopic stone surgery.
Identifiants
pubmed: 34784458
pii: apm.21066
doi: 10.17085/apm.21066
pmc: PMC9091677
doi:
Types de publication
Journal Article
Langues
eng
Pagination
157-164Références
Korean J Anesthesiol. 2020 Dec;73(6):471-485
pubmed: 32209961
J Investig Allergol Clin Immunol. 2018;28(4):216-232
pubmed: 29411702
J Pain Res. 2018 Jan 04;11:103-110
pubmed: 29379311
PLoS One. 2014 Dec 10;9(12):e114239
pubmed: 25493435
Korean J Anesthesiol. 2016 Dec;69(6):563-567
pubmed: 27924195
Anesth Analg. 2007 Jan;104(1):84-91
pubmed: 17179249
Anesth Analg. 2016 Apr;122(4):1141-6
pubmed: 26771265
Paediatr Anaesth. 1999;9(4):283-6
pubmed: 10411761
Can J Anaesth. 2010 Sep;57(9):843-8
pubmed: 20526708
Int J Med Sci. 2021 Jan 1;18(4):1075-1081
pubmed: 33456366
Lancet. 1994 Apr 16;343(8903):933-40
pubmed: 7512679
J Clin Pharm Ther. 2001 Apr;26(2):81-5
pubmed: 11350529
Medicine (Baltimore). 2019 Mar;98(10):e14763
pubmed: 30855478
Curr Ther Res Clin Exp. 2012 Dec;73(6):186-94
pubmed: 24653520
J Anesth. 2019 Apr;33(2):197-208
pubmed: 30603826
Anesth Analg. 2001 Jul;93(1):88-91
pubmed: 11429345
J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S42-52
pubmed: 14530788
Can J Anaesth. 1996 May;43(5 Pt 2):R116-28
pubmed: 8706214
Crit Care Med. 1999 Jul;27(7):1325-9
pubmed: 10446827
Br J Anaesth. 2018 Nov;121(5):1052-1058
pubmed: 30336849
Eur J Pharmacol. 2015 Apr 5;752:55-60
pubmed: 25697473
J Pain Symptom Manage. 2004 May;27(5):388-90
pubmed: 15120762
Br J Anaesth. 2010 Feb;104(2):216-23
pubmed: 20047899
J Int Med Res. 2015 Apr;43(2):226-35
pubmed: 25637216